vs
Celldex Therapeutics, Inc.（CLDX）与奎斯特诊断（IMDX）财务数据对比。点击上方公司名可切换其他公司
奎斯特诊断的季度营收约是Celldex Therapeutics, Inc.的9.5倍（$1.1M vs $120.0K）。奎斯特诊断净利率更高（-2015.4% vs -67764.2%，领先65748.8%）。奎斯特诊断同比增速更快（-23.4% vs -89.8%）。奎斯特诊断自由现金流更多（$-7.0M vs $-65.2M）。过去两年奎斯特诊断的营收复合增速更高（154.4% vs -12.3%）
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
奎斯特诊断公司是一家美国临床检验企业，跻身财富500强，业务覆盖美国本土，以及波多黎各、墨西哥、巴西等地区，同时与全球多家医院和诊所保持合作关系，是行业内颇具影响力的医疗诊断服务提供商。
CLDX vs IMDX — 直观对比
营收规模更大
IMDX
是对方的9.5倍
$120.0K
营收增速更快
IMDX
高出66.4%
-89.8%
净利率更高
IMDX
高出65748.8%
-67764.2%
自由现金流更多
IMDX
多$58.2M
$-65.2M
两年增速更快
IMDX
近两年复合增速
-12.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $120.0K | $1.1M |
| 净利润 | $-81.3M | $-23.0M |
| 毛利率 | — | 42.5% |
| 营业利润率 | -72628.3% | -2057.5% |
| 净利率 | -67764.2% | -2015.4% |
| 营收同比 | -89.8% | -23.4% |
| 净利润同比 | -72.7% | 31.5% |
| 每股收益（稀释后） | $-1.23 | $-0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDXIMDX
| Q4 25 | $120.0K | $1.1M | ||
| Q3 25 | $0 | $260.0K | ||
| Q2 25 | $730.0K | $518.0K | ||
| Q1 25 | $695.0K | $2.1M | ||
| Q4 24 | $1.2M | $1.5M | ||
| Q3 24 | $3.2M | $115.0K | ||
| Q2 24 | $2.5M | $104.0K | ||
| Q1 24 | $156.0K | $176.0K |
净利润CLDXIMDX
| Q4 25 | $-81.3M | $-23.0M | ||
| Q3 25 | $-67.0M | $-10.9M | ||
| Q2 25 | $-56.6M | $-9.7M | ||
| Q1 25 | $-53.8M | $-6.7M | ||
| Q4 24 | $-47.1M | $-33.5M | ||
| Q3 24 | $-42.1M | $-13.5M | ||
| Q2 24 | $-35.8M | $-4.5M | ||
| Q1 24 | $-32.8M | $-9.1M |
毛利率CLDXIMDX
| Q4 25 | — | 42.5% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | — | 62.0% | ||
| Q4 24 | — | 40.0% | ||
| Q3 24 | — | 43.5% | ||
| Q2 24 | — | 48.1% | ||
| Q1 24 | — | 25.6% |
营业利润率CLDXIMDX
| Q4 25 | -72628.3% | -2057.5% | ||
| Q3 25 | — | -4249.2% | ||
| Q2 25 | -8747.5% | -1900.0% | ||
| Q1 25 | -9027.2% | -318.0% | ||
| Q4 24 | -4768.3% | -2262.9% | ||
| Q3 24 | -1633.5% | -11752.2% | ||
| Q2 24 | -1854.2% | -4453.8% | ||
| Q1 24 | -26030.8% | -5265.3% |
净利率CLDXIMDX
| Q4 25 | -67764.2% | -2015.4% | ||
| Q3 25 | — | -4174.6% | ||
| Q2 25 | -7753.4% | -1880.7% | ||
| Q1 25 | -7740.4% | -312.0% | ||
| Q4 24 | -4007.8% | -2255.1% | ||
| Q3 24 | -1320.0% | -11733.0% | ||
| Q2 24 | -1434.8% | -4355.8% | ||
| Q1 24 | -21030.8% | -5186.9% |
每股收益（稀释后）CLDXIMDX
| Q4 25 | $-1.23 | $-0.75 | ||
| Q3 25 | $-1.01 | $-0.34 | ||
| Q2 25 | $-0.85 | $-0.30 | ||
| Q1 25 | $-0.81 | $-0.26 | ||
| Q4 24 | $-0.71 | $-2.19 | ||
| Q3 24 | $-0.64 | $-0.98 | ||
| Q2 24 | $-0.54 | $-0.36 | ||
| Q1 24 | $-0.56 | $-1.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $518.6M | $11.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $527.2M | $-31.5M |
| 总资产 | $583.0M | $25.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLDXIMDX
| Q4 25 | $518.6M | $11.6M | ||
| Q3 25 | $583.2M | $18.7M | ||
| Q2 25 | $630.3M | $24.3M | ||
| Q1 25 | $673.3M | $31.0M | ||
| Q4 24 | $725.3M | $8.6M | ||
| Q3 24 | $756.0M | $3.4M | ||
| Q2 24 | $802.3M | $9.3M | ||
| Q1 24 | $823.8M | $5.6M |
股东权益CLDXIMDX
| Q4 25 | $527.2M | $-31.5M | ||
| Q3 25 | $598.4M | $-9.2M | ||
| Q2 25 | $655.4M | $1.1M | ||
| Q1 25 | $703.0M | $10.2M | ||
| Q4 24 | $747.0M | $-12.3M | ||
| Q3 24 | $785.9M | $9.7M | ||
| Q2 24 | $813.7M | $22.7M | ||
| Q1 24 | $838.6M | $11.6M |
总资产CLDXIMDX
| Q4 25 | $583.0M | $25.8M | ||
| Q3 25 | $648.4M | $43.9M | ||
| Q2 25 | $692.4M | $50.5M | ||
| Q1 25 | $739.5M | $60.4M | ||
| Q4 24 | $792.3M | $35.1M | ||
| Q3 24 | $823.2M | $70.2M | ||
| Q2 24 | $845.6M | $74.7M | ||
| Q1 24 | $868.8M | $71.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.9M | $-5.5M |
| 自由现金流经营现金流 - 资本支出 | $-65.2M | $-7.0M |
| 自由现金流率自由现金流/营收 | -54350.8% | -616.7% |
| 资本支出强度资本支出/营收 | 1067.5% | 129.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-213.7M | $-25.4M |
8季度趋势，按日历期对齐
经营现金流CLDXIMDX
| Q4 25 | $-63.9M | $-5.5M | ||
| Q3 25 | $-48.6M | $-4.5M | ||
| Q2 25 | $-44.0M | $-6.3M | ||
| Q1 25 | $-54.4M | $-5.9M | ||
| Q4 24 | $-32.5M | $-5.4M | ||
| Q3 24 | $-55.3M | $-5.5M | ||
| Q2 24 | $-29.3M | $-6.0M | ||
| Q1 24 | $-40.6M | $-3.8M |
自由现金流CLDXIMDX
| Q4 25 | $-65.2M | $-7.0M | ||
| Q3 25 | $-49.1M | $-5.6M | ||
| Q2 25 | $-44.7M | $-6.6M | ||
| Q1 25 | $-54.6M | $-6.2M | ||
| Q4 24 | $-33.2M | $-5.6M | ||
| Q3 24 | $-55.9M | $-5.6M | ||
| Q2 24 | $-29.6M | $-6.2M | ||
| Q1 24 | $-41.0M | $-3.9M |
自由现金流率CLDXIMDX
| Q4 25 | -54350.8% | -616.7% | ||
| Q3 25 | — | -2135.4% | ||
| Q2 25 | -6127.8% | -1279.5% | ||
| Q1 25 | -7861.4% | -288.4% | ||
| Q4 24 | -2828.3% | -374.5% | ||
| Q3 24 | -1751.2% | -4884.3% | ||
| Q2 24 | -1185.0% | -5931.7% | ||
| Q1 24 | -26270.5% | -2189.8% |
资本支出强度CLDXIMDX
| Q4 25 | 1067.5% | 129.9% | ||
| Q3 25 | — | 403.8% | ||
| Q2 25 | 99.7% | 67.4% | ||
| Q1 25 | 38.1% | 14.4% | ||
| Q4 24 | 64.3% | 14.4% | ||
| Q3 24 | 17.1% | 75.7% | ||
| Q2 24 | 11.0% | 183.7% | ||
| Q1 24 | 220.5% | 13.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
